Evidence map›Paper›PMID 38911500›Full record

ReviewInternational journal of nanomedicine2024

The Advancing Role of Nanocomposites in Cancer Diagnosis and Treatment.

Vivian Andoh, Dickson Kofi Wiredu Ocansey, Hassan Naveed, Naijian Wang, Liang Chen, Keping Chen, Fei Mao

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Spatiotemporal cancer controlNanomedicine (London, England) · 2026
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Advances in nanomedicine and delivery systems for gastric cancer research.Frontiers in bioengineering and biotechnology · 2025
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Vivian Andoh *School of Life Sciences, Jiangsu University, Zhenjiang, People's Republic of China.ORCID 0000-0003-0590-5434
Dickson Kofi Wiredu Ocansey *Department of Laboratory Medicine, Lianyungang Clinical College, Jiangsu University, Lianyungang, Jiangsu, People's Republic of China.ORCID 0000-0003-3547-0857
Hassan NaveedSchool of Life Sciences, Jiangsu University, Zhenjiang, People's Republic of China.
Naijian WangKey Laboratory of Medical Science and Laboratory Medicine of Jiangsu Province, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, People's Republic of China.
Liang ChenSchool of Life Sciences, Jiangsu University, Zhenjiang, People's Republic of China.ORCID 0000-0003-4760-5165
Keping ChenSchool of Life Sciences, Jiangsu University, Zhenjiang, People's Republic of China.ORCID 0000-0001-5254-2299
Fei MaoDepartment of Laboratory Medicine, Lianyungang Clinical College, Jiangsu University, Lianyungang, Jiangsu, People's Republic of China.ORCID 0000-0001-5840-4436

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The relentless pursuit of effective cancer diagnosis and treatment strategies has led to the rapidly expanding field of nanotechnology, with a specific focus on nanocomposites. Nanocomposites, a combination of nanomaterials with diverse properties, have emerged as versatile tools in oncology, offering multifunctional platforms for targeted delivery, imaging, and therapeutic interventions. Nanocomposites exhibit great potential for early detection and accurate imaging in cancer diagnosis. Integrating various imaging modalities, such as magnetic resonance imaging (MRI), computed tomography (CT), and fluorescence imaging, into nanocomposites enables the development of contrast agents with enhanced sensitivity and specificity. Moreover, functionalizing nanocomposites with targeting ligands ensures selective accumulation in tumor tissues, facilitating precise imaging and diagnostic accuracy. On the therapeutic front, nanocomposites have revolutionized cancer treatment by overcoming traditional challenges associated with drug delivery. The controlled release of therapeutic agents from nanocomposite carriers enhances drug bioavailability, reduces systemic toxicity, and improves overall treatment efficacy. Additionally, the integration of stimuli-responsive components within nanocomposites enables site-specific drug release triggered by the unique microenvironment of the tumor. Despite the remarkable progress in the field, challenges such as biocompatibility, scalability, and long-term safety profiles remain. This article provides a comprehensive overview of recent developments, challenges, and prospects, emphasizing the transformative potential of nanocomposites in revolutionizing the landscape of cancer diagnostics and therapeutics. In Conclusion, integrating nanocomposites in cancer diagnosis and treatment heralds a new era for precision medicine.

Indexed as

NanocompositesNeoplasmsAnimalsAntineoplastic AgentsContrast MediaDrug CarriersDrug Delivery SystemsHumansMagnetic Resonance ImagingNanomedicineTomography, X-Ray ComputedAntineoplastic AgentsContrast MediaDrug Carrierscancerdiagnosisnanocompositesnanoparticlestheranostictherapy

Identifiers

PMID38911500
PMCPMC11194004

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.